Chart-Typ:
Zeitraum:
| Bristol Myers, Merck oder Jazz: Die besten Pharma-Aktien für die Quartalssaison | © Foto: Frank Rumpenhorst - dpaUS-Pharmaaktien haben den Markt zuletzt klar geschlagen - doch genau das macht sie anfällig. Bank of America nennt 4 Favoriten für die Quartalssaison und erklärt, warum... ► Artikel lesen |
| Oxford BioTherapeutics Partners Bristol Myers Squibb On T-Cell Engager Therapies For Solid Tumors | NEW YORK CITY (dpa-AFX) - Oncology company Oxford BioTherapeutics announced Thursday a multi-year, selective target collaboration with Bristol Myers Squibb Co. (BMY) focused on the discovery... ► Artikel lesen |
| Dividendenbekanntmachungen (02.04.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD 0,2501 EUR AKTIA BANK PLC FI4000058870 - 0,8 EUR ALICO INC US0162301040 0,05 USD 0,0431... ► Artikel lesen |
| Innocan Pharma Corporation: Innocan Pharma Announces Closing of Additional Debenture | The Debenture will bear interest at the rate of 10% per annum and matures at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed... ► Artikel lesen |
| Innocan Pharma Corporation: Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest | The Debenture will be on the same terms as the Prior Debenture and will bear interest at the rate of 10% per annum and will mature at the earlier of: (i) 12 months from the date of issuance; and (ii)... ► Artikel lesen |
| Innocan Pharma Corporation: Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M | Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.Our pharmaceutical segment is dedicated... ► Artikel lesen |
| Viatris Inc.: Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 | Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands
Expecting Impactful Near-Term... ► Artikel lesen |
| Viatris Outlines Long-term Financial Targets | WASHINGTON (dpa-AFX) - Viatris (VTRS) said, for combined long-term Targets through 2030, the company expects to deliver 5% to 6% total revenues CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10%... ► Artikel lesen |
| Dividendenbekanntmachungen (09.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANSIX INC US00773T1016 0,16 USD 0,1377 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2496 EUR ALPHABET INC CDR CA02080K1049 0... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.